Jennifer M. Taylor, MD, MPH

Jennifer M. Taylor, MD, MPH

Houston, Texas

Baylor College of Medicine

Dr. Taylor is an Assistant Professor of Urology at Baylor College of Medicine in Houston, Texas. She serves as the Associate Residency Program Director and Director of Preclinical and Clinical Urology Courses for medical students. She is a member of the Dan L. Duncan Comprehensive Cancer Center at Baylor and the Cancer Committee at the Michael E. DeBakey VA Medical Center. She currently practices urologic oncology at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center. Dr. Taylor received her undergraduate education from Barnard College in New York City. She went on to earn her MD from the University of Texas Medical School in Houston, and completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York City. She also earned an MPH from the Harvard TH Chan School of Public Health in Boston. Dr. Taylor is involved in clinical research in multiple GU malignancies, with a focus on bladder cancer, as well as research in medical education. Dr. Taylor is involved in the national medical community and is a member of the American Urological Association, the Society of Urologic Oncology, the Society of Women in Urology, and the American College of Surgeons.

Disclosures:

Articles by Jennifer M. Taylor, MD, MPH

Immunotherapy for NMIBC: Emerging and Expanding Indications

Jennifer M. Taylor, MD, MPH, Assistant Professor of Urology at Baylor College of Medicine in Houston, Texas, reviews new indications for immunotherapy for non-muscle invasive bladder cancer (NMIBC). She discusses the most common immunotherapy option, presents active clinical trials, and evaluates new treatment options. AUA guidance has previously stated that immunotherapy should be reserved for highest-risk NMIBC, and that for lower-risk cancer, patients and clinicians should weigh the benefit ratio when considering whether immunotherapy is an appropriate treatment choice given the possibility of adverse events. However, a shortage of the most common intravesical immunotherapy, bacillus Calmette-Guerin (BCG), in combination with increased numbers of BCG-unresponsive patients, have altered the treatment landscape. Dr. Taylor reviews the 2018 definition of BCG-unresponsive NMIBC and identifies several ways to determine whether a patient is BCG-unresponsive. Finally, she discusses the approval of pembrolizumab as a newly-available treatment for BCG-unresponsive NMIBC. In the study that led to the approval, 41% of patients had a complete response and no patients progressed to muscle invasive bladder cancer or metastasis. These favorable results are notable given that the gold-standard alternative is radical cystectomy. Additionally, pembrolizumab is well-tolerated and while adverse immune-related events are serious, they are rare and can be managed. Other treatments are also currently under investigation.

Read More

Case-Based Panel Discussion: Muscle-Invasive Bladder Cancer

A. Edward Yen, MD; Jennifer M. Taylor, MD, MPH; Guilherme Godoy, MD, MPH; and Seth P. Lerner, MD, examine four unique case examples to elaborate on various treatment approaches for muscle-invasive bladder cancer (MIBC) based on individual patient needs. The panel discussion reviews current data on neoadjuvant chemotherapy, trimodal therapy, and checkpoint inhibitors in this setting.

Read More

Bladder Cancer and Immunotherapy

Jennifer M. Taylor, MD, MPH, provides a brief overview of the basic scientific concepts of cancer cell suppression with checkpoint inhibitors. She also reviews the initial clinical trials for atezolizumab and pembrolizumab, larger trials for various immunotherapies for bladder cancer, toxicity reports, and ongoing research regarding these drugs in different combinations and disease states.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -